Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Composition : Ondansetron HCL I.P. 8mg
Dosage Form : Injection
Packaging Type : vial
Packaging : 5x1ml
Price : ₹1/-
Ondotyle 8 is a highly effective injectable formulation containing Ondansetron Hydrochloride I.P. at a concentration of 8 mg per injection. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that is primarily used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery. By blocking the action of serotonin, a neurotransmitter that can trigger nausea and vomiting, Ondotyle 8 provides rapid relief for patients undergoing treatments that may induce these distressing symptoms. The injection is particularly beneficial for patients who are unable to take oral medications due to nausea or vomiting, ensuring that they receive the necessary antiemetic therapy. Ondotyle 8 is administered intravenously or intramuscularly by healthcare professionals, allowing for quick absorption and onset of action. This makes it an ideal choice in acute care settings, such as hospitals or clinics, where immediate relief from nausea and vomiting is required. In addition to its primary use in oncology and postoperative care, Ondansetron has also been found effective in managing nausea and vomiting in various other clinical scenarios, including gastroenteritis and motion sickness. The safety profile of Ondotyle 8 is well-established, making it a preferred choice among healthcare providers for managing nausea and vomiting in diverse patient populations. Patients receiving Ondotyle 8 may experience improved comfort and quality of life during their treatment regimens, as effective control of nausea can significantly enhance their overall experience. Regular monitoring and appropriate dosing adjustments are essential to ensure optimal therapeutic outcomes while minimizing potential side effects.
Ondotyle 8 is a highly effective injectable formulation containing Ondansetron Hydrochloride I.P. at a concentration of 8 mg per injection. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that is primarily used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery. By blocking the action of serotonin, a neurotransmitter that can trigger nausea and vomiting, Ondotyle 8 provides rapid relief for patients undergoing treatments that may induce these distressing symptoms.
The injection is particularly beneficial for patients who are unable to take oral medications due to nausea or vomiting, ensuring that they receive the necessary antiemetic therapy. Ondotyle 8 is administered intravenously or intramuscularly by healthcare professionals, allowing for quick absorption and onset of action. This makes it an ideal choice in acute care settings, such as hospitals or clinics, where immediate relief from nausea and vomiting is required.
In addition to its primary use in oncology and postoperative care, Ondansetron has also been found effective in managing nausea and vomiting in various other clinical scenarios, including gastroenteritis and motion sickness. The safety profile of Ondotyle 8 is well-established, making it a preferred choice among healthcare providers for managing nausea and vomiting in diverse patient populations.
Patients receiving Ondotyle 8 may experience improved comfort and quality of life during their treatment regimens, as effective control of nausea can significantly enhance their overall experience. Regular monitoring and appropriate dosing adjustments are essential to ensure optimal therapeutic outcomes while minimizing potential side effects.
Common side effects may include headache, dizziness, constipation, and fatigue. Rarely, allergic reactions or changes in heart rhythm may occur, requiring immediate medical attention.
Ondotyle 8 is indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery.
Administer only under the supervision of a qualified healthcare professional. Not recommended for patients with known hypersensitivity to Ondansetron or other 5-HT3 antagonists.
Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children.
Composition : Ondansetron (8 mg) MD
Composition : Ondansetron (2mg)
Composition : Ondansetron (4mg) MD
Composition : Ondansetron (2mg) + Ranitidine (25mg)
Composition : Dicyclomine (10mg) + Ranitidine (150mg) + Simethicone (20mg)
Composition : Ranitidine (75mg/5ml)
Composition : Ondansetron (4mg) + Rabeprazole (20mg)
Composition : Levosulpiride (75mg) + Rabeprazole (20mg)